Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.
J Mol Endocrinol. 2019 Jul 1;63(1):51-61. doi: 10.1530/JME-18-0261.
Thyroid cancer is associated with one of the most malignant endocrine tumors. However, molecular mechanisms underlying thyroid tumorigenesis and progression remain unclear. In order to investigate these mechanisms, we performed whole-transcriptome sequencing, which indicated that a differentially expressed gene, METTL7B, was highly expressed in thyroid cancers. We analyzed METTL7B expression using TCGA and performed qRT-PCR on tissue samples. Moreover, an analysis of clinicopathological characteristics revealed a positive correlation between METTL7B and lymph node metastasis. A series of in vitro experiments indicated that METTL7B enhanced migration and invasion of thyroid carcinoma cells. Further studies revealed that METTL7B may enhance TGF-β1-induced epithelial-mesenchymal transition (EMT). Our results indicate that METTL7B may promote metastasis of thyroid cancer through EMT and may therefore be considered as a potential biomarker for the diagnosis and prognosis of thyroid carcinoma.
甲状腺癌与最恶性的内分泌肿瘤之一有关。然而，甲状腺肿瘤发生和进展的分子机制尚不清楚。为了研究这些机制，我们进行了全转录组测序，结果表明差异表达基因 METTL7B 在甲状腺癌中高表达。我们使用 TCGA 分析了 METTL7B 的表达，并在组织样本上进行了 qRT-PCR。此外，对临床病理特征的分析表明，METTL7B 与淋巴结转移呈正相关。一系列体外实验表明，METTL7B 增强了甲状腺癌细胞的迁移和侵袭。进一步的研究表明，METTL7B 可能增强 TGF-β1 诱导的上皮-间充质转化（EMT）。我们的结果表明，METTL7B 可能通过 EMT 促进甲状腺癌的转移，因此可被视为甲状腺癌诊断和预后的潜在生物标志物。
Zotero 插件